Cargando…

Interpretation of Discordant Rifampicin Susceptibility Test Results Obtained Using GeneXpert vs Phenotypic Drug Susceptibility Testing

BACKGROUND: The 3-month difference in turnaround time between Xpert and conventional phenotypic drug susceptibility testing (pDST) causes patient treatment challenges when pDST rifampin (RIF) susceptibility results and earlier Xpert results disagree, resulting in unnecessary tuberculosis (TB) patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huo, Fengmin, Ma, Yifeng, Liu, Rongmei, Ma, Liping, Li, Shanshan, Jiang, Guanglu, Wang, Fen, Shang, Yuanyuan, Dong, Lingling, Pang, Yu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7397830/ https://www.ncbi.nlm.nih.gov/pubmed/32766385 http://dx.doi.org/10.1093/ofid/ofaa279

Ejemplares similares

Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda
por: Ssengooba, Willy, et al.
Publicado: (2021)

Equivalence of the GeneXpert System and GeneXpert Omni System for tuberculosis and rifampicin resistance detection
por: Georghiou, Sophia B., et al.
Publicado: (2021)

Reevaluating Rifampicin Breakpoint Concentrations for Mycobacterium tuberculosis Isolates with Disputed rpoB Mutations and Discordant Susceptibility Phenotypes
por: Wang, Wei, et al.
Publicado: (2022)

Surveillance of Rifampicin Resistance With GeneXpert MTB/RIF in the National Reference Laboratory for Tuberculosis at the Institut Pasteur in Bangui, 2015–2017
por: Farra, Alain, et al.
Publicado: (2019)

rpoB Mutations Causing Discordant Rifampicin Susceptibility in Mycobacterium tuberculosis: Retrospective Analysis of Prevalence, Phenotypic, Genotypic, and Treatment Outcomes
por: Mvelase, Nomonde R, et al.
Publicado: (2019)

Impact of Decentralized Care and the Xpert MTB/RIF Test on Rifampicin-Resistant Tuberculosis Treatment Initiation in Khayelitsha, South Africa
por: Cox, Helen S., et al.
Publicado: (2015)

Detection of Mycobacterium tuberculosis (MTB) in Fecal Specimens From Adults Diagnosed With Pulmonary Tuberculosis Using the Xpert MTB/Rifampicin Test
por: Kokuto, Hiroyuki, et al.
Publicado: (2015)

GeneXpert MTB/RIF assay in the diagnosis of urinary tuberculosis from urine specimens
por: Pang, Yu, et al.
Publicado: (2017)

More Than a Decade of GeneXpert(®) Mycobacterium tuberculosis/Rifampicin (Ultra) Testing in South Africa: Laboratory Insights from Twenty-Three Million Tests
por: da Silva, Manuel Pedro, et al.
Publicado: (2023)

Performance of GeneXpert MTB/RIF for Diagnosing Tuberculosis Among Symptomatic Household Contacts of Index Patients in South Africa
por: Velen, Kavindhran, et al.
Publicado: (2021)

Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
por: Ssengooba, Willy, et al.
Publicado: (2021)

Diagnostic Accuracy of GeneXpert MTB/RIF Assay in Comparison to Conventional Drug Susceptibility Testing Method for the Diagnosis of Multidrug-Resistant Tuberculosis
por: Pandey, Pratikshya, et al.
Publicado: (2017)

Role of GeneXpert MTB/RIF assay for the diagnosis of cervical lymph node tuberculosis and rifampicin resistance
por: Mukhida, Sahjid, et al.
Publicado: (2022)

Missed opportunities for integrated testing of HIV and tuberculosis on the GeneXpert platform in Lesotho
por: Gwaza, Gamuchirai P., et al.
Publicado: (2023)

Clinical evaluation of the GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV combination test
por: Johnson, Grant, et al.
Publicado: (2021)

Old test for the diagnosis of novel corona virus infection: Role of GeneXpert in COVID-19 testing
por: Singh, Harpreet, et al.
Publicado: (2020)

An observational report of universal GeneXpert testing of inpatients with diagnosed or presumptive TB in the Philippines
por: Thi, Aye Myat, et al.
Publicado: (2020)

Evaluation of GeneXpert MTB/RIF for determination of rifampicin resistance among new tuberculosis cases in west and northwest Iran
por: Atashi, S., et al.
Publicado: (2017)

Detection of Mycobacterium Tuberculosis and Rifampicin-Resistant Gene among Hemodialysis Patients in Khartoum, Sudan: Using GeneXpert Assay
por: Mohamed, Balsam Adil, et al.
Publicado: (2020)

Detection of Mycobacterium tuberculosis and Rifampicin Resistance Using GeneXpert MTB/RIF Assay at Enat Hospital, Central Ethiopia
por: Selfegna, Sebsib, et al.
Publicado: (2022)

Comparative Performance of Line Probe Assay and GeneXpert in the Detection of Rifampicin Monoresistance in a TB-Endemic African Country
por: Mchaki, Betty R., et al.
Publicado: (2022)

Assessment of the Diagnostic Utility of GeneXpert Mycobacterium tuberculosis/Rifampicin (MTB/RIF) Assay in the Suspected Cases of Tuberculous Meningitis
por: Patel, Sakshi, et al.
Publicado: (2023)

Prevalence of rifampicin resistant pulmonary tuberculosis using geneXpert assay in Ethiopia, a systematic review and meta-analysis
por: Demelash, Maritu, et al.
Publicado: (2023)

Evaluation of the GeneXpert for Human Monkeypox Diagnosis
por: Li, Daniel, et al.
Publicado: (2017)

GeneXpert for the diagnosis of COVID-19 in LMICs
por: Rakotosamimanana, Niaina, et al.
Publicado: (2020)

Contributions of GeneXpert(®) to TB diagnosis in Myanmar
por: Burger, Z., et al.
Publicado: (2022)

Phenotypic drug susceptibility characterization and clinical outcomes of tuberculosis strains with A-probe mutation by GeneXpert MTB/RIF
por: Nie, Qi, et al.
Publicado: (2023)

Implementation of GeneXpert for TB Testing in Low- and Middle-Income Countries: A Systematic Review
por: Brown, Scott, et al.
Publicado: (2021)

Rifampicin-resistant Mycobacterium tuberculosis by GeneXpert MTB/RIF and Associated Factors Among Presumptive Pulmonary Tuberculosis Patients in Nepal
por: Sah, Shiv Kumar, et al.
Publicado: (2020)

GeneXpert MTB/RIF Outperforms Mycobacterial Culture in Detecting Mycobacterium tuberculosis from Salivary Sputum
por: Shi, Jin, et al.
Publicado: (2018)

Detection of Mycobacterium tuberculosis Rifampicin Resistance Conferred by Borderline rpoB Mutations: Xpert MTB/RIF is Superior to Phenotypic Drug Susceptibility Testing
por: Xia, Hui, et al.
Publicado: (2022)

GeneXpert—A Game-Changer for Tuberculosis Control?
por: Evans, Carlton A.
Publicado: (2011)

GeneXpert for TB diagnosis: planned and purposeful implementation
por: Piatek, Amy S, et al.
Publicado: (2013)

GeneXpert in stool: Diagnostic yield in Intestinal Tuberculosis
por: Talib, Abu, et al.
Publicado: (2019)

Molecular Epidemiology of Rifampicin Resistance in Mycobacterium tuberculosis Using the GeneXpert MTB/RIF Assay from a Rural Setting in India
por: Reddy, Raghuprakash, et al.
Publicado: (2017)

Comparison of GeneXpert and line probe assay for detection of Mycobacterium tuberculosis and rifampicin-mono resistance at the National Tuberculosis Reference Laboratory, Kenya
por: Aricha, S. A., et al.
Publicado: (2019)

Using quality improvement to improve the utilisation of GeneXpert testing at five lab hubs in Northern Uganda
por: Karamagi, Esther, et al.
Publicado: (2017)

Multidisease testing for HIV and TB using the GeneXpert platform: A feasibility study in rural Zimbabwe
por: Ndlovu, Zibusiso, et al.
Publicado: (2018)

Validation of GeneXpert testing for SARS-CoV-2 RNA in eight hospital laboratories in Oman
por: Al-Kindi, Nawal, et al.
Publicado: (2021)

WHO laboratory validation of Xpert(®) CT/NG and Xpert(®) TV on the GeneXpert system verifies high performances
por: Jacobsson, Susanne, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_an9329iana43tcb9hs4t0q7ekj